Related Experiment Video
Updated: Feb 16, 2026

Using Magnetometry to Monitor Cellular Incorporation and Subsequent Biodegradation of Chemically Synthetized Iron Oxide Nanoparticles
Published on: February 27, 2021
Probing the interaction of zero valent iron nanoparticles with blood system by biophysical, docking, cellular, and
Babak Abbaszadeh Asl1, Leila Mogharizadeh2, Niloofar Khomjani1
1Department of Cellular and Molecular Biology, Faculty of Advance Science and Technology, Pharmaceutical Sciences Branch, Islamic Azad University of Tehran (IAUPS), Iran.
Abstract:
Human exposure to nanoparticles (NPs) is inevitable as NPs become more widely applied and, as a result, nanotoxicology study is now gaining attention. Herein, the interaction of zero valent iron NPs (ZVFe-NPs) with human hemoglobin (Hb) was evaluated using a variety of techniques including fluorescence spectroscopy, far circular dichroism (CD) spectroscopy as well as docking study. Also, the cytotoxicity of ZVFe-NPs on the human lymphocyte cell line as a model of blood system cell line was investigated by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acridine orange/ethidium bromide (AO/EB) staining, flow cytometry, and real-time PCR assays. Fluorescence studies revealed that ZVFe-NPs bind to Hb via hydrogen bonds and induced conformational changes of Hb in a static denaturation mechanism. CD experiment showed that Hb retained its native structure in the presence of ZVFe-NP. Molecular docking study also demonstrated that polar residues of Hb provide convenient medium to establish hydrogen bonds with water molecules on ZVFe-NP surface. Likewise, it was also revealed that ZVFe-NPs impaired the viability of lymphocyte cells through apoptotic pathway. For NPs to move into the clinical area, it is crucial that nanotoxicology research provide pivotal information about the adverse effect of NPs against biological systems.
Related Concept Videos
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
The Equilibrium Binding Constant and Binding Strength

